Butyric acid in irritable bowel syndrome

Przeglad Gastroenterologiczny

Volumn 8, Issue 6, 2013, Pages 350-353

  Załȩski, Andrzej ^a   Banaszkiewicz, Aleksandra ^a   Walkowiak, Jarosław ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Butyric acid; Irritable bowel syndrome; Sodium butyrate

Indexed keywords

BUTYRIC ACID; BUTYRIC ACID DERIVATIVE;

DRUG MECHANISM; HUMAN; IRRITABLE COLON; NONHUMAN; PATHOGENESIS; REVIEW;

EID: 84892635705     PISSN: 18955770     EISSN: 18974317     Source Type: Journal    
DOI: 10.5114/pg.2013.39917     Document Type: Review

References (29)

1. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
2. Ziółkowski BA, Pacholec A, Kudlicka M, et al. Prevalence of abdominal symptoms in the Polish population. Prz Gastroenterol 2012; 7: 20-5.
3. http://www.romecriteria.org/criteria/
4. Brandt LJ, CheyWD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104: 1-35.
5. Ga̧siorowska J, Czerwionka-Szaflarska M. Small intestinal bacterial overgrowth syndrome and irritable bowel syndrome. Prz Gastroenterol 2013; 8: 165-71.
6. Respondek W, Tomasiuk R, Jarosz M, et al. Is it reasonable to perform serological tests for celiac disease in patients with irritable bowel syndrome? Prz Gastroenterol 2013; 8: 184-90.
7. Nehring P, Mrozikiewicz-Rakowska B, Krasnodȩbski P, et al. Irritable bowel syndrome - a new approach to aetiopathogenesis. Prz Gastroenterol 2011; 6: 17-22.
8. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332-40.
9. Banasiewicz T, Kaczmarek E, Maik J, et al. Quality of life and the clinical symptoms at the patients with irritable bowel syndrome treated complementary with protected sodium butyrate. Gastroenterol Prakt 2011; 5: 45-53.
10. Banasiewicz T, Kaczmarek E, Maik J, et al. The influence of protected sodium butyrate on frequency and severity some clinical symptoms at the patients with irritable bowel syndrome. Gastroenterol Prakt 2012; 1: 16-23.
11. Tarnowski W, Borycka-Kiciak K, Kiciak A, et al. Outcome of treatment with butyric acid In irritable bowel syndrome - preliminary report. Gastroenterol Prakt 2011; 1: 43-8.
12. Rechkemmer G, Rönnau K, von Englehardt W. Fermentation of polisaccharides and absorption of short chain fatty acids in the mammalian hindgut. Comp Biochem Physiol 1988; 90: 563-8.
13. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev 2001; 81: 31-64.
14. Scheppach W, Bartram P, Richter A, et al. Effect of short-chain fatty acids on the human colonic mucosa in vitro. J Parenter Enteral Nutr 1992; 16: 43-8.
15. Roy CC, Kien CL, Bouthillier L, et al. Short-chain fatty acids: ready for prime time? Nutr Clin Pract 2006; 21: 351-66.
16. Charney AN, Micic L, Egnor RW. Nonionic diffusion of short-chain fatty acids across rat colon. Am J Physiol 1998; 274: 518-24.
17. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of colonic mucosa in man. Gut 1980; 21: 793-8.
18. Hold GL, Schwiertz A, Aminov RI, et al. Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces. Appl Environ Microbiol 2003; 69: 4320-4.
19. Bird AR, Conlon MA, Christophersen CT, et al. Resistant starch, large bowel fermentation and a broader perspective of prebiotics and probiotics. Benef Microbes 2010; 1: 423-31.
20. Chen CC, Walker WA. Probiotics and prebiotics: role in clinical disease states. Adv Pediatr 2005; 52: 77-113.
21. Rabbani GH, Akbert MJ, Hamidur Rahman AS, et al. Short-chain fatty acids improve clinical, pathologic, and micobiologic features of experimental shigellosis. J Infect Dis 1999; 179: 390-7.
22. Rabbani GH, Albert MJ, Rahman H, et al. Short-chain fatty acids inhibit fluid and electrolyte loss induced by cholera toxin in proximal colon of rabbit in vivo. Dig Dis Sci 1999; 44: 1547-53.
23. Velázquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. Production, absorption, metabolism and therapeutic implications. Adv Exp Med Biol 1997; 427: 123-34.
24. Gálfi P, Bokori J. Feeding trail in pigs with a diet containing sodium n-butyrate. Acta Vet Hung 1990; 38: 3-17.
25. Kotunia A, Woliñski J, Laubitz D, et al. Effect of sodium butyrate on the small intestine development in neonatal piglets fed by artificial sow. J Physiol Pharmacol 2004; 55: 59-68.
26. Andoh A, Bamba T, Saski M. Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. J Parent Enteral Nutr 1999; 23: 70-3.
27. Mishiro T, Kusunoki R, Otani A, et al. Butyric acid attenuates intestinal inflammation in murine DSS-induced colitis model via milk fat globule-EGF factor 8. Lab Invest 2013; 93: 834-43.
28. Breuer RI, Soergel KH, Lashner BA, et al. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 1997; 40: 485-91.
29. Pinto A, Fidalgo P, Cravo M, et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double-blind, controlled trial. Dis Colon Rectum 1999; 42: 788-95.